UBS Group Raises Encompass Health (NYSE:EHC) Price Target to $110.00

Encompass Health (NYSE:EHC) had its target price upped by analysts at UBS Group from $100.00 to $110.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. UBS Group’s target price suggests a potential upside of 14.17% from the stock’s previous close.

Several other research analysts have also weighed in on the stock. Truist Financial lifted their price objective on shares of Encompass Health from $100.00 to $104.00 and gave the stock a “buy” rating in a research note on Thursday, August 15th. Leerink Partners began coverage on shares of Encompass Health in a report on Wednesday, July 10th. They issued an “outperform” rating and a $100.00 price target on the stock. Barclays decreased their price target on Encompass Health from $113.00 to $109.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Stephens reiterated an “overweight” rating and set a $105.00 target price on shares of Encompass Health in a research report on Tuesday, August 6th. Finally, Leerink Partnrs raised shares of Encompass Health to a “strong-buy” rating in a research report on Wednesday, July 10th. Nine research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $101.63.

Encompass Health Price Performance

Encompass Health stock traded up $1.09 on Wednesday, reaching $96.35. The company’s stock had a trading volume of 258,311 shares, compared to its average volume of 636,091. The business’s fifty day moving average price is $90.35 and its 200 day moving average price is $85.62. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.35 and a current ratio of 1.35. The company has a market cap of $9.69 billion, a price-to-earnings ratio of 26.04, a PEG ratio of 1.41 and a beta of 0.88. Encompass Health has a twelve month low of $57.55 and a twelve month high of $96.93.

Encompass Health (NYSE:EHC) last posted its quarterly earnings data on Monday, August 5th. The company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.10. The firm had revenue of $1.30 billion during the quarter, compared to analysts’ expectations of $1.30 billion. Encompass Health had a net margin of 7.88% and a return on equity of 17.83%. Encompass Health’s revenue was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.95 EPS. Equities analysts expect that Encompass Health will post 4.18 earnings per share for the current fiscal year.

Encompass Health declared that its Board of Directors has initiated a stock repurchase program on Wednesday, July 24th that authorizes the company to buyback $500.00 million in shares. This buyback authorization authorizes the company to purchase up to 5.4% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board believes its shares are undervalued.

Insider Activity

In other news, CFO Douglas E. Coltharp sold 12,260 shares of the business’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $86.34, for a total value of $1,058,528.40. Following the transaction, the chief financial officer now directly owns 136,227 shares of the company’s stock, valued at approximately $11,761,839.18. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Principal Securities Inc. bought a new position in Encompass Health in the 4th quarter worth about $25,000. Parallel Advisors LLC increased its holdings in shares of Encompass Health by 192.3% in the fourth quarter. Parallel Advisors LLC now owns 573 shares of the company’s stock worth $38,000 after buying an additional 377 shares during the period. Oakworth Capital Inc. bought a new stake in Encompass Health in the 2nd quarter worth $40,000. Benjamin F. Edwards & Company Inc. raised its stake in Encompass Health by 58.9% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 534 shares of the company’s stock worth $46,000 after buying an additional 198 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in Encompass Health by 31.9% during the 1st quarter. GAMMA Investing LLC now owns 616 shares of the company’s stock valued at $51,000 after acquiring an additional 149 shares during the period. 97.25% of the stock is owned by institutional investors.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.